APELLIS PHARMACEUTICALS INC's ticker is APLS and the CUSIP is 03753U106. A total of 213 filers reported holding APELLIS PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.31 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $3,312,000 | -11.1% | 73,232 | -0.1% | 0.03% | +3.4% |
| Q1 2022 | $3,727,000 | +7.6% | 73,340 | +0.1% | 0.03% | +11.5% |
| Q4 2021 | $3,463,000 | -28.0% | 73,242 | -49.8% | 0.03% | -16.1% |
| Q3 2021 | $4,808,000 | +6.8% | 145,868 | +104.9% | 0.03% | -20.5% |
| Q2 2021 | $4,500,000 | +47.4% | 71,195 | +0.1% | 0.04% | +34.5% |
| Q1 2021 | $3,052,000 | -24.9% | 71,127 | +0.1% | 0.03% | -31.0% |
| Q4 2020 | $4,066,000 | +76.6% | 71,090 | +0.8% | 0.04% | +40.0% |
| Q3 2020 | $2,303,000 | -1.3% | 70,525 | -1.3% | 0.03% | -6.2% |
| Q2 2020 | $2,334,000 | +22.0% | 71,481 | +0.1% | 0.03% | -8.6% |
| Q1 2020 | $1,913,000 | -15.4% | 71,396 | -3.2% | 0.04% | 0.0% |
| Q4 2019 | $2,260,000 | +2.4% | 73,783 | -16.0% | 0.04% | +2.9% |
| Q3 2019 | $2,208,000 | +104.3% | 87,879 | +106.0% | 0.03% | +70.0% |
| Q2 2019 | $1,081,000 | +478.1% | 42,650 | +201.4% | 0.02% | +300.0% |
| Q4 2018 | $187,000 | – | 14,150 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Octagon Capital Advisors LP | 3,130,000 | $119,065,200 | 18.29% |
| EcoR1 Capital, LLC | 10,899,859 | $414,630,636 | 13.99% |
| Ally Bridge Group (NY) LLC | 181,805 | $6,915,862 | 8.12% |
| Avoro Capital Advisors LLC | 11,111,111 | $422,666,662 | 6.59% |
| ACUTA CAPITAL PARTNERS, LLC | 244,484 | $9,300,171 | 6.23% |
| Iron Triangle Partners LP | 880,000 | $33,475,200 | 4.89% |
| Cormorant Asset Management, LP | 2,000,000 | $76,080,000 | 4.44% |
| Octagon Capital Advisors LP | 675,000 | $25,677,000 | 3.94% |
| Logos Global Management LP | 750,000 | $28,530,000 | 3.81% |
| Boxer Capital, LLC | 1,726,000 | $65,657,040 | 3.50% |